Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy

References

• LawrenceMDaujatSSchneiderRLateral thinking: how histone modifications regulate gene expressionTrends Genet2016321425626704082
   PubMed Web of Science ®Google Scholar
• VankateshSWorkmanJLHistone exchange, chromatin structure and the regulation of transcriptionNature Rev Mol Cell Biol201516317818925650798
   PubMed Web of Science ®Google Scholar
• HarrJCGonzalez-SandovalAGasserSMHistone and histone modifications in perinuclear chromatin anchoring: from yeast to manEMBO Rep201617213915526792937
   PubMed Web of Science ®Google Scholar
• VerdinEOttM50 Years of protein acetylation: from gene regulation to epigenetics, metabolism and beyondNat Rev Mol Cell Biol201516425826425549891
   PubMed Web of Science ®Google Scholar
• DuJJohnsonLMJacobsenSEPatelDJDNA methylation pathways and their crosstalk with histone methylationNat Rev Mol Cell Biol201516951953226296162
   PubMed Web of Science ®Google Scholar
• GreerELShiYHistone methylation: a dynamic mark in health, disease and inheritanceNat Rev Genet201213534335722473383
   PubMed Web of Science ®Google Scholar
• Russler-GermainDASpencerDHYoungMAThe R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramersCancer Cell201425444245424656771
   PubMed Web of Science ®Google Scholar
• SpencerDHRussler-GermainDAKetkarSCpG island hypermethylation mediated by DNMT3A is a consequence of AML progressionCell2017168580181628215704
   PubMed Web of Science ®Google Scholar
• DayYJWangYYHuangJYConditional knockin of DNMT3A R878H initiates acute myeloid leukemia with mTOR pathway involvementProc Natl Acad Sci U S A2017114205237524228461508
   PubMed Web of Science ®Google Scholar
• ShenYZhuYMFanXGene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemiaBlood2011118205593560321881046
   PubMed Web of Science ®Google Scholar
• LinPHLiHYFanSCA targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practiceCancer Med20176234936028070990
   PubMed Web of Science ®Google Scholar
• MizunoSChijwaTOkamuraTExpression of DNA methyltransferases DNMT1A, 3A and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemiaBlood20019751172117911222358
   PubMed Web of Science ®Google Scholar
• TrowbridgeJJSinhaAUZhuNLiMArmstrongSAOrkinSHHaploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domainsGenes Dev201226234434922345515
   PubMed Web of Science ®Google Scholar
• YanFShenNPangJXA vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic targetLeukemia Epub20171010
   Web of Science ®Google Scholar
• ShenNYanFPangJXInactivation of receptor tyrosine kinases reverts aberrant DNA methylation in acute myeloid leukemiaClin Cancer Res201723206254626628720666
   PubMed Web of Science ®Google Scholar
• TagdeARajabiHStroopinskyDMUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemiaOncotarget2016726389743898727259275
   PubMedGoogle Scholar
• ArgoteJADasanuCAASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcome and survivalCurr Med Res Opin Epub2017124
   Web of Science ®Google Scholar
• GaidzikVITeleanuVPapaemmanuilERUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic featuresLeukemia201630112160216827137476
   PubMed Web of Science ®Google Scholar
• OhgamiRSMaLMerkerJDNext-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutationsMod Pathol201528570671425412851
   PubMed Web of Science ®Google Scholar
• LundKAdamsPDCoplandMEZH2 in normal and malignant hematopoiesisLeukemia2014281444924097338
   PubMed Web of Science ®Google Scholar
• GöllnerSOellerichTAgrawal-SinghSLoss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemiaNat Med2017231697827941792
   PubMed Web of Science ®Google Scholar
• GaoLSunJLiuFZhangHMaYHigher expression levels of the HOXA9 gene, closely associated with MLL-PTD and EZH2 mutations, predict inferior outcome in acute myeloid leukemiaOnco Targets Ther2016971172226929642
   PubMed Web of Science ®Google Scholar
• SunQYDingLWTanKTOrdering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD)Leukemia201731111027389053
   PubMed Web of Science ®Google Scholar
• CaoQGearhartMGerySBCOR regulates myeloid cell proliferation and differentiationLeukemia20163051155116526847029
   PubMed Web of Science ®Google Scholar
• PapaemmanuilEGerstungMBullingerLGenomic classification and prognosis in acute myeloid leukemiaN Eng J Med20163742322092221
   PubMed Web of Science ®Google Scholar
• ShiraiCILeyJNWhiteBSMutant U2AF1 expression alters hematopoiesis and pre-mRNA splicing in vivoCancer Cell201527563164325965570
   PubMed Web of Science ®Google Scholar
• KimEIlaganJOLiangYSRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognitionCancer Cell201527561763025965569
   PubMed Web of Science ®Google Scholar
• DöhnerHEsteyEGrimwadeDDiagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood2017129442444727895058
   PubMed Web of Science ®Google Scholar
• WintersABerntKMLL-rearranged leukemias: an update on science and clinical approachesFront Pediatr20175428232907
   PubMed Web of Science ®Google Scholar
• BasilicoSGöttgensBDysregulation of haematopoietic stem cell regulatory program in acute myeloid leukemiaJ Mol Med (Berl)201795771972728429049
   PubMed Web of Science ®Google Scholar
• RoseDHaferlachTSchnittgerSPerglerováKKernWHaferlachCSubtype-specific patterns of molecular mutations in acute myeloid leukemiaLeukemia2017311111727285584
   PubMed Web of Science ®Google Scholar
• TsaiCHHouHATangJLGenetic alterations and their clinical implications in older patients with acute myeloid leukemiaLeukemia20163071485149227055875
   PubMed Web of Science ®Google Scholar
• GaidzikVIPaschkaPSpäthDTET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study groupJ Clin Oncol201230121350135722430270
   PubMed Web of Science ®Google Scholar
• MagotraMSakhdariALeePJImmunohistochemical loss of 5-hydroxymethylcytosine expression in acute myeloid leukemia: relationship to somatic gene mutations affecting epigenetic pathwaysHistopathology201696610551065
   Web of Science ®Google Scholar
• AhnJSKimHJKimYK5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemiaOncotarget2017858305831428039446
   PubMedGoogle Scholar
• SperlingASGibsonCJEbertBLThe genetics of myelodysplastic syndrome: from clonal hematopoiesis to secondary leukaemiaNat Rev Cancer201717151927834397
   PubMed Web of Science ®Google Scholar
• CimminoLDolgalevIWangYRestoration of TET2 function blocks aberrant self-renewal and leukemia progressionCell2017170710781095.e20
   Google Scholar
• MedeirosBCFathiATDiNardoCDPollyeaDAChanSMSwordsRIsocitrate dehydrogenase mutations in myeloid malignanciesLeukemia201731227228127721426
   PubMed Web of Science ®Google Scholar
• ChenCLiuYLuCCancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Bdr4 inhibitionGenes Dev201327181974198524065765
   PubMed Web of Science ®Google Scholar
• MarcucciGMaharryKWuYZIDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyJ Clin Oncol201028142348235520368543
   PubMed Web of Science ®Google Scholar
• SteinEMDiNardoCDPollyeaDAEnasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemiaBlood2017130672273128588020
   PubMed Web of Science ®Google Scholar
• LinPHLiHYFanSCA targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practiceCancer Med20176234936028070990
   PubMed Web of Science ®Google Scholar
• BullingerLDöhnerKDöhnerHGenomics of acute myeloid leukemia diagnosis and pathwaysJ Clin Oncol201735993494628297624
   PubMed Web of Science ®Google Scholar
• HacklHAstaninaKWieserRMolecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemiaJ Hematol Oncol20171015128219393
   PubMed Web of Science ®Google Scholar
• KumimotoHNakajimaHEpigenetic dysregulation of hematopoietic stem cells and preleukemic stateInt J Hematol20171061344428555413
   PubMed Web of Science ®Google Scholar
• ZinkFStaceySNNorddahlGLClonal hematopoiesis, with and without candidate driver mutations, is common in the elderlyBlood2017130674275228483762
   PubMed Web of Science ®Google Scholar
• FigueroaMELugthartSLiYDNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemiaCancer Cell2010171132720060365
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkGenomic and epigenomic landscape of adult de novo acute myeloid leukemiaN Engl J Med2013368222059207423634996
   PubMed Web of Science ®Google Scholar
• AkalinAGarrett-BakelmanFEKormakssonMBase-pair resolution DNA methylation sequencing reveals profoundly diver-gent epigenetic landscapes in acute myeloid leukemiaPLoS Genet201286e100278122737091
   PubMed Web of Science ®Google Scholar
• SchoofsTBerdelWEMüller-TidowCOrigins of aberrant DNA methylation in acute myeloid leukemiaLeukemia201428111423958917
   PubMed Web of Science ®Google Scholar
• MarcucciGYanPMaharryKEpigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene scoreJ Clin Oncol201432654855624378410
   PubMed Web of Science ®Google Scholar
• FigueroaMEAbdel-WahabOLuCLeukemic IDH1 and IDH2 mutations result in hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiationCancer Cell201018655356721130701
   PubMed Web of Science ®Google Scholar
• LuskinMRGimottyPASmithCA clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemiaJCI Insight201619e8732327446991
   PubMed Web of Science ®Google Scholar
• LiSGarrett-BakelmanFChungSDistinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemiaNat Med2012227792799
   Web of Science ®Google Scholar
• VardimanJWThieleJArberDAThe 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesBlood2009114593795119357394
   PubMed Web of Science ®Google Scholar
• ArberDAOraziAHasserjianRThe 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemiaBlood2016127202391240527069254
   PubMed Web of Science ®Google Scholar
• KantajianHRobozGKropfPGuadecitabine (SG-110) in treatment-naïve patients with acute myeloid leukemia: phase 2 results from a multicenter, randomized, phase 1–2 trialLancet Oncol2017101813171326
   Web of Science ®Google Scholar
• KropfPLChungWBKellyADGenetic determinants of response to guadecitabine (SG-110) in AMLBlood2016128221680
   Web of Science ®Google Scholar
• DaverNKantarjianHMRobozGJLong term survival and clinical complete responses of various prognostic subgroups in 103 relapsed/refractory acute myeloid leukemia (r/r AML) patients treated with guadecitabine (SG-110) in phase 2 studiesBlood201612822904
   Web of Science ®Google Scholar
• WelchJSPettiAAMillerCATP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromesN Engl J Med21163752120232036
   Google Scholar
• SebertMBallyCPeterlinPResults of a phase II study of guadecitabine (SGI-110) in higher risk MDS, CMML or low blast count AML patients refractory to or relapsing after azacitidine (AZA) treatmentBlood201612822347
   Web of Science ®Google Scholar
• Montaban-BravoGBosePAlvaradoYInitial results of a phase 2 study of guadecitabine (SGI-110), a novel subcutaneous (SC) hypomethylating agent, for patients with previously untreated intermediate-2 or high risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML)Blood201612822346
   Web of Science ®Google Scholar
• MetregerLWissmannMYinNLSD1 demethylates repressive histone marks to promote androgen receptor-dependent transcriptionNature2005437705743643916079795
   PubMed Web of Science ®Google Scholar
• HøjfeldtJWAggerKHelinKHistone lysine demethylases as targets for anticancer therapyNat Rev Drug Discov2013121291793024232376
   PubMed Web of Science ®Google Scholar
• StavropoulosPBlobelGHoelzACrystal structure and mechanism of human lysine-specific demethylase-1Nat Struct Mol Biol200613762663216799558
   PubMed Web of Science ®Google Scholar
• ChenYYangYWangFCrystal structure of human histone lysine-specific demethylase 1 (LSD1)Proc Natl Acad Sci U S A200610338139561396116956976
   PubMed Web of Science ®Google Scholar
• FornerisFBindaCVanoniMAHuman histone demethylase LSD1 reads the histone codeJ Biol Chem200528050413604136516223729
   PubMed Web of Science ®Google Scholar
• FornerisFBindaCVanoniMAMatteviABattaglioliEHistone demethylation catalyzed by LSD1 is a flavin-dependent oxidative processFEBS Lett2005579102203220715811342
   PubMed Web of Science ®Google Scholar
• TongJKHassigCASchnitzlerGRKingstonRESchreiberSLChromatin deacetylation by an ATP-dependent nucleosome remodeling complexNature199839567059179219804427
   PubMed Web of Science ®Google Scholar
• HumphreyGWWangYRussanovaVRStable histone deacetylase complexes distinguished by the presence of SANT domain protein CoREST/kiaa0071 and Mta-L1J Biol Chem200127696817682411102443
   PubMed Web of Science ®Google Scholar
• YouATongJKGrozingerCMSchreiberSLCoREST is an integral component of the CoREST-human histone deacetylase complexProc Natl Acad Sci U S A20019841454145811171972
   PubMed Web of Science ®Google Scholar
• HakimiMADongYLaneWSSpeicherDWShiekhattarRA candidate X-linked mental retardation gene is a component of a new family of histone deacetylase-containing complexesJ Biol Chem200327897234723912493763
   PubMed Web of Science ®Google Scholar
• DiazAMSomervailleTLSD1: biologic roles and therapeutic targetingEpigenomics2016881103111627479862
   PubMed Web of Science ®Google Scholar
• ZhengYCMaJWangZA systematic review of histone lysine-specific demethylase 1 and its inhibitorsMed Res Rev20153551032107125990136
   PubMed Web of Science ®Google Scholar
• ZibettiCAdamoABindaCAlternative splicing of the histone demethylase LSD1/KDM1 contributes to the modulation of neurite morphogenesis in the mammalian nervous systemJ Neurosci20103072521253220164337
   PubMed Web of Science ®Google Scholar
• SprüsselASchulteJHWeberSLysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiationLeukemia20122692039205122699452
   PubMed Web of Science ®Google Scholar
• KerenyiMAShaoZHsuYJHistone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturationElife20132e0063323795291
   PubMed Web of Science ®Google Scholar
• UpadhyayGChowdhuzyAVaidyanathanBKimDSalequeSAntagonistic actions of Rcor proteins regulate LSD1 activity and cellular differentiationProc Natl Acad Sci U S A2014111228071807624843136
   PubMed Web of Science ®Google Scholar
• SalequeSKimJRookeHMOrkinSHEpigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1Mol Cell200727456257217707228
   PubMed Web of Science ®Google Scholar
• AnguitaECandelFJChaparroARoldán-EtcheverryJJTranscription factor GFl1B in health and diseaseFront Oncol201775428401061
   PubMedGoogle Scholar
• HuXLiXValverdeKLSD1-mediated epigenetic modification is required for TAL-1 function and hematopoiesisProc Natl Acad Sci U S A200910625101411014619497860
   PubMed Web of Science ®Google Scholar
• LiYDengCHuXDynamic interaction between TAL1 oncoprotein and LSD1 regulates TAL1 junction in hematopoiesis and leukemogenesisOncogene201231485007501822310283
   PubMed Web of Science ®Google Scholar
• XuJBauerDEKerenyiMACorepressor-dependent silencing of fetal hemoglobin expression by BCL11AProc Natl Acad Sci U S A2013110166518652323576758
   PubMed Web of Science ®Google Scholar
• GuoYFuXJinYHistone demethylase LSD1-mediated repression of GATA-2 is critical for erythroid differentiationDrug Des Devel Ther2015931533162
   PubMed Web of Science ®Google Scholar
• VelinderMSingerJBareyanDGFl1 functions in transcriptional control and cell fate determination require SNAG domain methylation to recruit LSD1Biochem J2016473193355336927480105
   PubMed Web of Science ®Google Scholar
• ThambyrajahRMazanMPatelRGFl1 proteins orchestrate the emergence of haematopoietic stem cells through recruitment of LSD1Nat Cell Biol2016181213226619147
   PubMed Web of Science ®Google Scholar
• TakeuchiMFuseYWatanabeMLSD1/KDM1A promotes hematopoietic commitment of hemangioblasts through downregulation of Etv2Proc Natl Acad Sci U S A201511245139221392726512114
   PubMed Web of Science ®Google Scholar
• MöröyTVanenLWilkesBKhandanpourCFrom cytopenia to leukemia: the role of GFi1 and GFi1b in blood formationBlood201512642561256926447191
   PubMed Web of Science ®Google Scholar
• HönesJMBotezatuLHelnessAGFI1 as a novel prognostic and therapeutic factor for AML/MDSLeukemia20163021237124526847026
   PubMed Web of Science ®Google Scholar
• VolpeGWaltonDSGraingerDEPrognostic significance of high GFI1 expression in AML of normal karyotype and its association with a FLT3-ITD signatureSci Rep2017711114828894287
   PubMed Web of Science ®Google Scholar
• YaoHGoldmanDCNechiporukTCorepressor Rcor1 is essential for murine erythropoiesisBlood2014123203175318424652990
   PubMed Web of Science ®Google Scholar
• YaoHGoldmanDCFanGThe corepressor Rcor1 is essential for normal myeloerythroid lineage differentiationStem Cells201533113304331426119982
   PubMed Web of Science ®Google Scholar
• NiebelDKirfelJJanzenVHöllerTMajoresMGütgemannILysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasmsBlood2014124115115224993879
   PubMed Web of Science ®Google Scholar
• HarrisWJHuangXLynchJTThe histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cellsCancer Cell201221447348722464800
   PubMed Web of Science ®Google Scholar
• GoardonNMarchiEAtzbergerACoexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemiaCancer Cell201119113815221251617
   PubMed Web of Science ®Google Scholar
• WadaTKoyamaDKikuchiJHondaHFurukawaYOverexpression of the shortest isoform of histone demethylase LSD1 primes hemopoietic stem cells for malignant transformationBlood2015125243731374625904247
   PubMed Web of Science ®Google Scholar
• SchenkTChenWCGöllnerSInhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemiaNat Med201218460561122406747
   PubMed Web of Science ®Google Scholar
• NiwaHUmeharaTStructural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylasesEpigenetics201712534035228277979
   PubMed Web of Science ®Google Scholar
• LeeMGWynderCSchmidtDMMcCaffertyDGShiekhattarRHistone H3 lysine 4 demethylation is a target of nonselective antidepressive medicationChem Biol200613656356716793513
   PubMed Web of Science ®Google Scholar
• ZhengYCYuBChenZSLiuYLiuHMTCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapyEpigenomics20168565166627102879
   PubMed Web of Science ®Google Scholar
• MaesTTirapuIMascaroAPreclinical characterization of a potent and selective inhibitor of the histone demethylase KDM1A for MLL leukemiaJ Clin Oncol20133115 Supple13543
   Web of Science ®Google Scholar
• SomervailleTSalameroOMontesimosPSafety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary activity in acute leukemia of Ory-1001, a first-in-class inhibitor of lysine-specific histone demethylase 1A (LSD1/KDM1A): initial results from a first-in-human phase 1 studyPoster presented at: 58th American Society of Hematology Annual MeetingDecember 3–6, 2016San Diego, CA
   Google Scholar
• NeelamegamRRicqELMalvaezMBrain-penetrant LSD1 inhibitors can block memory consolidationACS Chem Neurosci20123212012822754608
   PubMed Web of Science ®Google Scholar
• CuiSLimKCShiLThe LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduced disease pathology in sickle cell miceBlood2015126338639626031919
   PubMed Web of Science ®Google Scholar
• JagadeeswaranRVazquezBAThiruppathiMPharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cell of sickle cell diseaseExp Hematol201750465228238805
   PubMed Web of Science ®Google Scholar
• RiversAVaitkusKIbanezVThe LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis)Haematologica2016101668869726858356
   PubMed Web of Science ®Google Scholar
• IbanezIVaitkusKRiversAEfficacy and safety of long-term RN-1 treatment to increase HbF in baboonsBlood2017129226026327908882
   PubMed Web of Science ®Google Scholar
• McGrathJWilliamsonKEBalasubramanianSPharmacological inhibition of the histone lysine demethylase KDM1A suppresses the growth of multiple acute myeloid leukemia subtypesCancer Res20167671975198826837761
   PubMed Web of Science ®Google Scholar
• MohammadHPSmithemanKNKamatCDA DNA hypom-ethylation signature predicts antitumor activity of LSD1 inhibitors in SCLCCancer Cell2015281576926175415
   PubMed Web of Science ®Google Scholar
• LeeSHStubbsMLiuXMDiscovery of INCB059872, a novel FAD-directed LSD1 inhibitor that is effective in preclinical models of human and murine AMLCancer Res20167614 Suppl4712
   Web of Science ®Google Scholar
• YeMLiuMLuYThe LSD1 inhibitor INCB059872 is synergistic with ATRA in models of non-APL acute myelogenous leukemiaCancer Res20167614 Suppl469626980761
   PubMed Web of Science ®Google Scholar
• LiuXStubbsMYeMCombination of BET inhibitor INCB054329 and LSD1 inhibitor INCB059872 is synergistic for the treatment of AML in vitro and in vivoCancer Res20167614 Suppl4702
   Web of Science ®Google Scholar
• LeeSHStubbsMJuvekarACombination of epigenetic regulation via LSD1 inhibition with signal transduction inhibitors significantly enhances anti-tumor activity in models of hematologic malignanciesCancer Res20177713 Suppl2032
   Web of Science ®Google Scholar
• WelchDKahenECubittCLReedDRLSD1 inhibition alone and in combination with chemotherapy in Ewing sarcoma cell linesCancer Res20177713 Suppl2034
   Web of Science ®Google Scholar
• RomanVDYeMLiuHThe evaluation of INCB059872, an FAD-directed covalent inhibitor of LSD1, in preclinical models of Ewing sarcomaCancer Res20177713 Suppl1162
   Web of Science ®Google Scholar
• LeeSHLiuXMDiamondMThe evaluation of INCB059872, on FAD-directed inhibitor of LSD1, in preclinical models of human small cell lung cancerCancer Res20177614 Suppl4704
   Google Scholar
• IshikawaYGamoKYabukiMA novel LSD1 inhibitor T-3775440 disrupts GFI1B-containing complex leading to transdifferentiation and impaired growth of AML cellsMol Cancer Ther201616227328427903753
   PubMed Web of Science ®Google Scholar
• OgasawaraDItohYTsumotoHLysine-specific demethylase 1-selective inactivators: protein targeted drug delivery mechanismAngew Chem Int Ed Engl201352338620862423824985
   PubMed Web of Science ®Google Scholar
• SuginoMKawaharaMTatsumiGA novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancersLeukemia201731112303231428210006
   PubMed Web of Science ®Google Scholar
• OgasawaraDSuzukiTMinoKSynthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitorBioorg Med Chem201119123702370821227703
   PubMed Web of Science ®Google Scholar
• SareddyGRViswanadhapalliSSurapaneniPSuzukiTBrennerAVadlamudiRKNovel KDm1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathwayOncogene201736172423243427893719
   PubMed Web of Science ®Google Scholar
• MouldDPMcGouagleAEWisemanDHWilliamsELJordanAMReversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to dateMed Res Rev201535358661825418875
   PubMed Web of Science ®Google Scholar
• SornaVTheisenERStephensBHigh-throughput virtual screening identifies novel N′-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitorsJ Med Chem201356239496950824237195
   PubMed Web of Science ®Google Scholar
• FiskusWSharmaSShahBHighly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cellsLeukemia201428112155216424699304
   PubMed Web of Science ®Google Scholar
• LiuSALuWTLiSYIdentification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce [sic] apoptosis and autophagy of AML cellsOncotarget2017819319013191428404874
   PubMedGoogle Scholar
• VianelloPSartoriLAmigoniFThieno [3,2-b]pyrrole-5- carboxiamides as new reversible inhibition of histone lysine demethylase KDM1A/LSD1 – part 2: structure-based drug design and structure-activity relationshipJ Med Chem20176051693171528186757
   PubMed Web of Science ®Google Scholar
• MouldDPAlliCBrembergUDevelopment of (4-cyanophenyl) glycine derivatives as reversible inhibitors of lysine specific demethylase 1J Med Chem201760197984799928892629
   PubMed Web of Science ®Google Scholar
• MouldDPBrembergUJordanAMDevelopment and evaluation of 4-(pyrrolidin-3-yl) benzonitrile derivatives as inhibitors of LSD1Bioorg Med Chem Lett201727204755475928927796
   PubMed Web of Science ®Google Scholar
• DuanYCMaYCQinWPDesign and synthesis of tranylcypromine derivatives as novel LSD1/HDAC dual inhibitors for cancer treatmentEur J Med Chem201714039240228987602
   PubMed Web of Science ®Google Scholar
• McLeanCMKaremakerIDvan LeeuwenFThe emerging roles of DOT1L in leukemia and normal developmentLeukemia201428112131213824854991
   PubMed Web of Science ®Google Scholar
• FengQWangHNgHHMethylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domainCurr Biol200212121052105812123582
   PubMed Web of Science ®Google Scholar
• MinJFengQLiZZhangYXuRMStructure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferaseCell2003112571172312628190
   PubMed Web of Science ®Google Scholar
• OkadaYFengQLinYhDOT1L links histone methylation of leukemogenesisCell2005121216717815851025
   PubMed Web of Science ®Google Scholar
• NguyenATTaranovaOHeJZhangYDOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesisBlood2011117256912692221521783
   PubMed Web of Science ®Google Scholar
• DeshpandeAJDeshpandeASinhaAUAF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypesCancer Cell201426689690825464900
   PubMed Web of Science ®Google Scholar
• ChenSYangZWilkinsonAWThe PZP domain of AF10 senses unmodified H3K27 to regulate DOT1L-mediated methylation of H3K79Mol Cell201560231932726439302
   PubMed Web of Science ®Google Scholar
• LiYYWenHXiYXAF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylationCell2014159355857125417107
   PubMed Web of Science ®Google Scholar
• ChenCWKocheRPSinhaAUDOT1L inhibits SIRT1-mdiated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemiaNat Med201521433534325822366
   PubMed Web of Science ®Google Scholar
• KuntimaddiAAchilleNJThorpeJDegree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 di- and tri-methylation on target genes and transformation potentialCell Rep201511580882025921540
   PubMed Web of Science ®Google Scholar
• OkudaHStanogevicBKanaiACooperative gene activation by AF4 and DOT1L drive MLL-rearranged leukemiaJ Clin Invest201712751918193128394257
   PubMed Web of Science ®Google Scholar
• RanRRodriguezBLuoMDOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemiaBlood2016128797198127335278
   PubMed Web of Science ®Google Scholar
• FengYYangYOrtegaMMEarly mammalian erythropoiesis requires the Dot1L methyltransferaseBlood2010116224483449120798234
   PubMed Web of Science ®Google Scholar
• NguyenATHeJTaranovaOZhangYEssential role of DOT1L in maintaining normal adult hematopoiesisCell Res20112191370137321769133
   PubMed Web of Science ®Google Scholar
• JoSYGranowiczEMMaillardIThomasDHessJLRequirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocationBlood2011117184759476821398221
   PubMed Web of Science ®Google Scholar
• DaigleSROlhavaEJTherkelsenCASelective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitorCancer Cell2011201536521741596
   PubMed Web of Science ®Google Scholar
• DaigleSROlhavaEJTherkelsenCAPotent inhibition of DOT1L as treatment for MLL-fusion leukemiaBlood201312261017102523801631
   PubMed Web of Science ®Google Scholar
• YuWChoryEJWernimontAKCatalytic site remodeling of the DOT1L methyltransferase by selective inhibitorsNat Commun20123128823250418
   PubMed Web of Science ®Google Scholar
• WangYLiLZhangBDiscovery of novel disruptor of silencing telomeric 1-like (DOT1L) inhibitors using a target-specific function for the (s)-adenosyl-l-methionine (SAM)-dependent methyltransferase familyJ Med Chem20176052026203628165739
   PubMed Web of Science ®Google Scholar
• WatersNJDaigleSRRehlaenderBNExploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic targetJ Control Release2015220Pt B75876526385168
   PubMed Web of Science ®Google Scholar
• KlausCRIwanowiczDJohnstonDDOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged cellsJ Pharmacol Exp Ther2014350964665624993360
   PubMed Web of Science ®Google Scholar
• WatersNJSmithSAOlhavaEJMetabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and humanCancer Chemother Pharmacol2016771436226645404
   PubMed Web of Science ®Google Scholar
• SteinEMGarcia-ManeroGRizzieriDAA phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in adults with relapse or refractory leukemia: safety, clinical activity, exposure and target inhibitionBlood2015126232547
   Web of Science ®Google Scholar
• ShuklaNWetmoreCO’BrienMMFinal report of phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in children with relapsed or refractory MLL-2 acute leukemiaBlood2016128222780
   Web of Science ®Google Scholar
• ChandrasekharappaSCGuruSCManickamPPositional cloning of the gene for multiple endocrine neoplasia-type 1Science199727653114044079103196
   PubMed Web of Science ®Google Scholar
• GuruSCGoldsmithPKBurnsALMenin, the product of the MEN1 gene, is a nuclear proteinProc Natl Acad Sci U S A1998954163016349465067
   PubMed Web of Science ®Google Scholar
• YokoyamaASomervailleTCSmithKSRozenblatt-RosenOMeyersonMClearyMLThe menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesisCell2005123220721816239140
   PubMed Web of Science ®Google Scholar
• CasliniCYangZEl-OstaMMilneTASlanyRKHessJLInter-action of MLL amino terminal sequences with menin is required for transformationCancer Res200767157275728317671196
   PubMed Web of Science ®Google Scholar
• GrembeckaJBelcherAMHartleyTCierpickiTMolecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemiasJ Biol Chem201028552406904069820961854
   PubMed Web of Science ®Google Scholar
• ChenYXYanJKeeshanKThe tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expressionProc Natl Acad Sci U S A200610341018102316415155
   PubMed Web of Science ®Google Scholar
• HughesCMRozenblatt-RosenOMilneTAMenin associated with a trithorax family histone methyltransferase complex and with the Hoxc8 locusMol Cell200413458759714992727
   PubMed Web of Science ®Google Scholar
• CierpickiTGrembeckaJChanges and opportunities in targeting the menin-MLL interactionFuture Med Chem20146444746224635524
   PubMed Web of Science ®Google Scholar
• MuraiMJChruszczMReddyGGrembeckaJCierpickiTCrystal structure of menin binding site for mixed lineage leukemia (MLL) proteinJ Biol Chem201128636317423174821757704
   PubMed Web of Science ®Google Scholar
• GrembeckaJHeSShiAMenin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemiaNat Chem Biol20128327728422286128
   PubMed Web of Science ®Google Scholar
• HeSMalikBBorkinDMenin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent mannerLeukemia201630250851326084867
   PubMed Web of Science ®Google Scholar
• DafflonCCraigVJMéreauHComplementary activities of DOT1L and menin inhibitors in MLL-rearranged leukemiaLeukemia20173161269127727840424
   PubMed Web of Science ®Google Scholar
• SpencerDHYoungMALamprechtTLEpigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cellsLeukemia20152961279128925600023
   PubMed Web of Science ®Google Scholar
• KühnMWSongEFengZHTargeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemiaCancer Discov20166101166118127535106
   PubMed Web of Science ®Google Scholar
• FalchettiAGenetics of multiple endocrine neoplasia type 1 syndrome: what’s new and what’s oldF1000Res2017673
   Google Scholar
• SvobodaLKBaileyNVan NoordRATumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and meninOncotarget20178145847127888797
   PubMedGoogle Scholar
• MalikRKhanAPAsanganiIATargeting the MLL complex in castration-resistant prostate cancerNat Med201521434435225822367
   PubMed Web of Science ®Google Scholar
• HessJLYuBDLiBHansonRKorsmeyerSJDefects in yolk sac hematopoiesis in MLL-null embryosBlood1997905179918069292512
   PubMed Web of Science ®Google Scholar
• YagiHDeguchiKAonoAKishimotoTKomoriTGrowth disturbance in fetal liver hematopoiesis of MLL-mutant miceBlood19989211081179639506
   PubMed Web of Science ®Google Scholar
• ErnstPFisherJKAveryWWadeSFoyDKorsmeyerSJDefinitive hematopoiesis requires the mixed-lineage leukemia geneDev Cell20046343744315030765
   PubMed Web of Science ®Google Scholar
• JudeCDClimerLXuDArtingerEFisherJKErnstPUnique and independent roles for MLL in adult hematopoietic stem cells and progenitorsCell Stem Cell20071332433718371366
   PubMed Web of Science ®Google Scholar
• McMahonKAHiewSYHadjurSMLL has a critical role in fetal and adult hematopoietic stem cell self-renewalCell Stem Cell20071333834518371367
   PubMed Web of Science ®Google Scholar
• MaillardIChenYXFriedmanAMenin regulates the function of hematopoietic stem cells and lymphoid progenitorsBlood200911381661166919228930
   PubMed Web of Science ®Google Scholar
• MaillardIHessJLThe role of menin in hematopoiesisAdv Exp Med Biol2009668515720175452
   PubMed Web of Science ®Google Scholar
• LiBGanTMeyersonMRabbittsTHErnstPDistinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cellsBlood2013122122039204623908472
   PubMed Web of Science ®Google Scholar
• GantTJudeCDZaffutoKErnstPDevelopmentally induced MLL1 loss reveals defects in postnatal haematopoiesisLeukemia201024101732174120724987
   PubMed Web of Science ®Google Scholar
• MishraBPZaffutoKMArtingerELThe histone methyltransferase activity of MLL1 is dispensable for hematopoiesis and leukemogenesisCell Rep2014741239124724813891
   PubMed Web of Science ®Google Scholar
• ArtingerELMishraBPZaffutoKMAn MLL-dependent network sustains hematopoiesisProc Natl Acad Sci U S A201311029120001200523744037
   PubMed Web of Science ®Google Scholar
• GrembeckaJBelcherAMHartleyTCierpickiTMolecular basis of the mixed lineage leukemia-menin interaction: implication for targeting mixed lineage leukemiasJ Biol Chem201028552406904069820961854
   PubMed Web of Science ®Google Scholar
• DhiAMuraiMJHeSStructural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemiaBlood2012120234461446922936661
   PubMed Web of Science ®Google Scholar
• GrembeckaJHeSShiAMenin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemiaNat Chem Biol20128327728422286128
   PubMed Web of Science ®Google Scholar
• BorkinDHeSMiaoHPharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in vivoCancer Cell201527458960225817203
   PubMed Web of Science ®Google Scholar
• HeSSenterTJPollockJHigh-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interactionJ Med Chem20145741543155624472025
   PubMed Web of Science ®Google Scholar
• ZhouHLiuLHuangJStructure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL 1) protein-protein interactionJ Med Chem20135631113112323244744
   PubMed Web of Science ®Google Scholar
• LiLZhouRGengHDiscovery of two aminoglycoside antibiotics as inhibitors targeting the menin-mixed lineage leukemia interfaceBioorg Med Chem Lett20142492090209324709560
   PubMed Web of Science ®Google Scholar
• XuYYueLWangYDiscovery of novel inhibitors targeting the menin-mixed lineage leukemia interface using pharmacophore-and docking-based virtual screeningJ Chem Inf Model20165691847185527513308
   PubMed Web of Science ®Google Scholar
• BorkinDPollockJKempinskaKProperty focused structure-based optimization of small molecule inhibitors of the protein-protein interaction between menin and mixed lineage leukemiaJ Med Chem201659389291326744767
   PubMed Web of Science ®Google Scholar
• SpurrSSBayleEDYuWNew small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atomsBioorg Med Chem Lett201626184518452227485386
   PubMed Web of Science ®Google Scholar
• ChenCZhuHStaufferFDiscovery of novel Dot1L inhibitors through a structure-based fragmentation approachACS Med Chem Lett20167873574027563395
   PubMed Web of Science ®Google Scholar
• MöbitzHMachauerRHolzerPDiscovery of potent, selective, and structurally novel Dot1L inhibitors by a fragment linking approachACS Med Chem Lett20178333834328337327
   PubMed Web of Science ®Google Scholar